| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019
|
Herrscher, Hugo
|
|
|
149 |
C |
p. 91-93
|
artikel
|
| 2 |
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review
|
Zichi, Clizia
|
|
|
149 |
C |
p. 49-60
|
artikel
|
| 3 |
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
|
Provencio, Mariano
|
|
|
149 |
C |
p. 61-72
|
artikel
|
| 4 |
Applications of single-cell and bulk RNA sequencing in onco-immunology
|
Kuksin, Maria
|
|
|
149 |
C |
p. 193-210
|
artikel
|
| 5 |
Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients
|
Izzedine, Hassan
|
|
|
149 |
C |
p. 34-36
|
artikel
|
| 6 |
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy
|
Wiesweg, Marcel
|
|
|
149 |
C |
p. 211-221
|
artikel
|
| 7 |
Cemiplimab removed from reimbursable drugs in France
|
Pham, Félix
|
|
|
149 |
C |
p. 11-13
|
artikel
|
| 8 |
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification
|
Höhn, Julia
|
|
|
149 |
C |
p. 94-101
|
artikel
|
| 9 |
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
|
Jacquet, Emmanuelle
|
|
|
149 |
C |
p. 82-90
|
artikel
|
| 10 |
Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival
|
Jakobsen, Anders
|
|
|
149 |
C |
p. 128-133
|
artikel
|
| 11 |
Evidence-based recommendations on categories for extent of resection in diffuse glioma
|
Karschnia, Philipp
|
|
|
149 |
C |
p. 23-33
|
artikel
|
| 12 |
Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors
|
Kato, Shumei
|
|
|
149 |
C |
p. 184-192
|
artikel
|
| 13 |
High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment
|
El Sharouni, Mary-Ann
|
|
|
149 |
C |
p. 105-113
|
artikel
|
| 14 |
High levels of TNFα in patients with COVID-19 refractory to tocilizumab
|
Danlos, F.X.
|
|
|
149 |
C |
p. 102-104
|
artikel
|
| 15 |
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R
|
Ethier, Josee-Lyne
|
|
|
149 |
C |
p. 117-127
|
artikel
|
| 16 |
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
|
Ghisoni, E.
|
|
|
149 |
C |
p. 153-164
|
artikel
|
| 17 |
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
|
Grimmelmann, Imke
|
|
|
149 |
C |
p. 1-10
|
artikel
|
| 18 |
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
|
Tjulandin, Sergey
|
|
|
149 |
C |
p. 222-232
|
artikel
|
| 19 |
Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
|
Tanaka, Kentaro
|
|
|
149 |
C |
p. 14-22
|
artikel
|
| 20 |
Pericarditis during chemoimmunotherapy for non–small cell lung cancer: an adverse event to prevent and recognise
|
Jacobs, Francesca
|
|
|
149 |
C |
p. 114-116
|
artikel
|
| 21 |
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds
|
Haque, Abedul
|
|
|
149 |
C |
p. 165-183
|
artikel
|
| 22 |
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
|
Schettini, Francesco
|
|
|
149 |
C |
p. 134-152
|
artikel
|
| 23 |
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
|
Prelaj, Arsela
|
|
|
149 |
C |
p. 235-248
|
artikel
|
| 24 |
Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease
|
Rosell, Rafael
|
|
|
149 |
C |
p. 233-234
|
artikel
|
| 25 |
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
|
Dimitriou, Florentia
|
|
|
149 |
C |
p. 37-48
|
artikel
|
| 26 |
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression
|
Ochi, Nobuaki
|
|
|
149 |
C |
p. 73-81
|
artikel
|
Tijdschrift beschrijving